Epana Bio key facts
as of Oct 2026- Developer of targeted therapeutic systems designed for autoimmune disease treatment.
- Epana Bio is valued at approximately $27.0M as of Oct 2026 (last reported valuation).
- It has raised $14.0M; the latest was Seed Round ($11.0M) in Mar 2025.
- Notable investors include Impact Assets, South Park Commons, Hummingbird Ventures, Refactor Capital, Tao Capital Partners — 12 tracked in total.
- Status: Privately Held (backing).
Epana Bio's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Epana Bio: the Monday email on marks, rounds and moves
Epana Bio funding rounds
No funding rounds for Epana Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Epana Bio
12+Epana Bio valuation
Epana Bio's last reported valuation was $27 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Epana Bio investors
12 investors are on record for Epana Bio, including Impact Assets, South Park Commons, Hummingbird Ventures and Refactor Capital.
About Epana Bio
Developer of targeted therapeutic systems designed for autoimmune disease treatment. The company's platform integrates genomics analysis and artificial intelligence to identify and address the cellular origins of autoimmune disorders, supporting the discovery and development of precision medicines tailored to specific patient populations, enabling healthcare providers and patients in the autoimmune disease market to access therapies developed with a focused, data-driven approach aimed at improving treatment specificity and accelerating development timelines.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2024
- Website
- epana.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.